What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital?

Answer from: Medical Oncologist at Academic Institution

We treat resectable pancreatic patients with neoadjuvant therapy regardless. In a fit patient, we will recommend starting with FOLFIRINOX chemotherapy. Restaging scans should be fine every 2 months. We could consider therapy for 4-6 months.

Comments

Medical Oncologist at Novant Health Oncology Specialists
What would be recommended for patients not fit eno...

Medical Oncologist at Mayo Clinic
In the neoadjuvant setting where FOLFIRINOX is not...

Medical Oncologist at Novant Health Oncology Specialists
Thank you! Greatly helpful! Since Gem Abraxane has...

Please select the option that best describes you:

What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital?

Related Questions